March 3, 2026 · Executive Brief

World Birth Defects Day 2026

Connect prevention, surveillance, diagnosis, specialty care, and family support across the life course.

Written byGreg WahlstromMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 26 min read

The 2026 leadership signal

A diagnosis should open a coordinated life-course route.

Birth defects are a diverse group of structural or functional conditions with different causes, clinical needs, and outcomes. One label cannot substitute for condition-specific counseling and care.

The executive task spans prevention where evidence supports it, accurate surveillance, timely diagnosis, specialty access, developmental services, and practical support for families without blame or stigma.

Choose one high-impact condition and trace the route from detection or birth through confirmed diagnosis, referral, family communication, and first specialty visit.

U.S. frequency

1 in 33

CDC estimates that birth defects affect about 1 in every 33 babies born in the United States each year.

Newborn deaths

240,000

WHO estimates that congenital disorders cause about 240,000 newborn deaths worldwide within 28 days of birth each year.

Campaign date

March 3

The 2026 World Birth Defects Day activities were scheduled for March 3.

Figures are summarized from the authoritative sources linked below. Definitions and denominators should be read with each source.

Executive opening

Data that moves families forward

World Birth Defects Day is often framed around prevention messages. For health-system leaders, the operating question is narrower and harder. How fast does a diagnosis become a referral, and how reliably does that referral reach a family? Surveillance programs answer the first part, but rigorous case confirmation often introduces significant delay.^[1] In Utah, that delay was described as a barrier to timely family referrals for early intervention services.^[1]

The evidence now points to ways around that delay. Across 1245 potential cases in Utah, preliminary reviews by nonclinical staff had an overall mean positive predictive value of 68%.^[1] Accuracy reached 95% for musculoskeletal defects and 92% for chromosomal anomalies, which the authors judged sufficient to trigger early family-centered referrals.^[1] Texas has added electronic case reporting, which gives near-time notification of potential cases from facilities.^[2]

Prevention remains part of the picture, but it is less settled than campaign language suggests. A meta-analysis found mandatory folic acid fortification was associated with a 44% lower risk of neural tube defects.^[9] A critical review argued that many such studies do not account for changing socioeconomic conditions over time.^[10] Leaders can support prevention while being honest about what the evidence does and does not show. That honesty protects trust with families who have already experienced a congenital condition.

This brief adds evidence to the operating guidance above. It covers burden, surveillance quality, prevention reach, access, equity, the human infrastructure of registries and referral teams, and public communication. The goal is a pathway in which every journey has an accountable next step. Throughout, the evidence is drawn from surveillance programs, cohorts, reviews and economic models in several countries. Where findings come from other health systems, they are offered as design lessons rather than local benchmarks.

Executive angle

This observance gives healthcare executives an opportunity to improve detection, referral and family support for congenital conditions by strengthening the surveillance, prevention and early-referral pathway that links preconception care, birth hospitals, public health registries and specialty services.

Questions for the executive team

How quickly does a birth defect identified in our hospitals reach the state surveillance program, and how quickly does the family reach early intervention?
Are we using electronic case reporting, and do we know where its signals still need chart confirmation?
Which preconception and prenatal touchpoints reliably address folic acid, vaccination and chronic conditions such as hypertension and diabetes?
Which executive and board committee own maternal-child pathway measures from diagnosis to first specialty visit?

Do access to fortified foods, prenatal care and specialty services differ for Hispanic, rural, uninsured or limited-English communities we serve?
Do we have enough abstractors, genetic counselors and care coordinators to turn surveillance data into timely family referrals?
What will we measure at 30, 60 and 90 days to show that one congenital-condition referral pathway has become faster and more reliable?

Current evidence

Burden is concentrated where detection is weakest

Birth defects remain a substantial contributor to neonatal illness and death, especially in low- and middle-income countries.^[3] In a neonatal intensive care unit in Bangladesh, 183 of 5,223 admitted newborns (3.5%) had birth defects.^[3] Of those infants, 56 (30.6%) died, a 1.59-fold higher mortality risk than among newborns without defects.^[3] Musculoskeletal anomalies were the most common group, with 67 cases.^[3] Cleft lip or palate followed with 30 cases and circulatory anomalies with 29.^[3] The mix of conditions shows why one generic referral route cannot serve every diagnosis.

Population surveillance shows how much of the burden stays hidden in hospital counts. In eastern Ethiopia, population-based surveillance from June 2023 to May 2024 enrolled 126 neural tube defect cases.^[14] The birth prevalence was 98.7 per 10,000 births, but the prevalence in the population was only 1.8 per 10,000.^[14] Of the 126 cases, 78 (62%) died during the study period, including 68 in utero.^[14] High stillbirth rates and low survival explain the gap between the two measures.^[14]

Spina bifida accounted for 51.6% of those cases, and birth prevalence was highest in rural areas, at 128.7 per 10,000 births.^[14] Without population-level data, the authors noted, planning effective prevention and intervention is hindered.^[14] That lesson applies to U.S. systems that rely only on live-birth hospital data.

Patterns also shift over time. In a high-prevalence region of northern China, isolated congenital clubfoot showed a significant increasing trend after 2012 while non-isolated cases declined.^[7] The authors called for continued surveillance to clarify the factors behind the rise.^[7] Without stable surveillance, such changes would go unseen. Registries are the early warning system for congenital conditions, and their value depends on consistent case definitions over many years.

Infection remains a preventable driver. Rubella is the leading cause of vaccine-preventable birth defects.^[5] Global progress has been large: reported rubella cases fell 66% from 2012 to 2024, and modeled congenital rubella syndrome cases fell by about 70%.^[5] Yet in 2024, about 21 million infants aged 12 to 23 months lived in the 15 countries that had not introduced rubella vaccine.^[5] For U.S. systems, that gap is a reminder that immunity checks before pregnancy matter for patients who arrive from many countries. Rubella infection in pregnancy can bring miscarriage, fetal death, stillbirth or congenital rubella syndrome.^[5]

Figure 1

Prevention reach is high for vaccines and low for fortified ready-made foods

Percent of countries, children or products reached by a prevention measure, as reported in each study. Values are copied from the cited studies [5], [13]; none is estimated.

Data note. These values come from different studies, units and settings, so this is an indirect comparison; the bars show where prevention reach is strong or weak, not relative effectiveness.

Limitation. The rubella values are global and country-level; the corn masa values describe product availability in selected U.S. areas, not intake.

Figure data (4 rows)

Figure 1 data: Prevention reach is high for vaccines and low for fortified ready-made foods
Measure	Value	Population, setting and year as reported	Source
Countries using rubella-containing vaccine, 2024	92%	179 of 194 countries, worldwide	[5]
Global coverage with first routine rubella vaccine dose, 2024	73%	Worldwide estimate; 39% in 2012	[5]
Corn masa flour bags fortified with folic acid	50%	25 of 50 distinct products in 111 stores in selected areas of California, Georgia and Texas	[13]
Corn tortilla products fortified with folic acid	1%	2 of 178 distinct products in the same store survey	[13]

A family physician talks with a young couple planning a pregnancy about folic acid and routine vaccines. — Illustrative image. Preliminary record review by nonclinical staff was accurate enough for many conditions to support early family referral.^[1]

Continuum of care

From registry signal to family referral

The continuum for congenital conditions starts before conception and runs through diagnosis, referral and long-term services. Surveillance sits in the middle, and its speed shapes what follows. Utah’s multistage active surveillance is highly accurate but long and labor-intensive.^[1] Its validation study asked whether preliminary data were accurate enough to act on before final clinician confirmation.^[1]

The answer varied by condition, which matters for pathway design. Gastroschisis, limb deficiencies and trisomy 21 showed high stability, at 95%, 93% and 92%.^[1] Cardiovascular defects were less accurate at 78%, and complex conditions such as single ventricle reached only 8%.^[1] Even so, 77% of reclassified cardiovascular cases stayed within the same body system.^[1] A referral rule can therefore act early for stable conditions while routing complex cardiac cases for confirmation first. That kind of rule should be written jointly by the surveillance program, neonatal teams and early intervention partners.

Hospitals can speed the front end. Texas implemented electronic case reporting for birth defects surveillance in 2023.^[2] For critical congenital heart defects, electronic reports captured potential diagnoses more completely than facility discharge lists.^[2] Not all electronically identified diagnoses were confirmed by chart abstraction, so electronic reporting is not yet a viable source for confirmation.^[2] The practical design is a fast electronic signal paired with a reliable confirmation step. Executives should ask whether their own birth hospitals send these reports and who reviews what comes back.

Newborn examination is another handoff point. The Bangladesh study recommended routine neonatal examination in the community and in hospitals to support early detection and proper referral.^[3] Maternal hypertension and diabetes were strong predictors, which the authors said warrants targeted antenatal screening and timely intervention.^[3] Those findings link prenatal chronic disease management directly to newborn risk.

Registries can also answer questions that single hospitals cannot. New York linked its sexually transmitted infection surveillance registry with its birth defects registry for births from 2010 to 2020.^[4] Adequate first-trimester chlamydia treatment was not associated with a lower risk of selected birth defects, and the authors called for further study of timing.^[4] Linked data of this kind help health systems test assumptions before building pathways on them. They also show the value of keeping registry partnerships active between observances, so the data are ready when a question arises.

Figure 3

Why the pathway breaks

People

Limited abstractor and clinician confirmation capacity
Low clinical awareness of emerging infections
Few coordinators to carry referrals to families

Process

Final confirmation required before any family referral
No routine newborn examination outside hospitals
Prenatal hypertension and diabetes not linked to newborn risk review

Technology

Electronic case reports not yet reliable for confirmation
Few diagnostic assays for some infections
Registries not linked to other surveillance data

Environment

Rural communities with high stillbirth and low survival
Few fortified ready-made staple foods
Countries without rubella vaccine

Policy

Voluntary rather than required fortification of some foods
Insufficient fortification levels in some national policies
Debated ethics of mandatory fortification

Measurement

Facility counts miss stillbirths and deaths
Accuracy of preliminary data not measured by condition
Time from diagnosis to referral not tracked

Unranked qualitative cause-and-effect diagram for the outcome in the box: Families of infants with congenital conditions wait too long for confirmed diagnosis and referral to early intervention and specialty care Causes are assembled from the cited literature [1], [2], [3], [4], [5], [6], [8], [10], [13], [14]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)

Figure 3 data: Why the pathway breaks
Category	Causes drawn from the cited literature
People	Limited abstractor and clinician confirmation capacity; Low clinical awareness of emerging infections; Few coordinators to carry referrals to families
Process	Final confirmation required before any family referral; No routine newborn examination outside hospitals; Prenatal hypertension and diabetes not linked to newborn risk review
Technology	Electronic case reports not yet reliable for confirmation; Few diagnostic assays for some infections; Registries not linked to other surveillance data
Environment	Rural communities with high stillbirth and low survival; Few fortified ready-made staple foods; Countries without rubella vaccine
Policy	Voluntary rather than required fortification of some foods; Insufficient fortification levels in some national policies; Debated ethics of mandatory fortification
Measurement	Facility counts miss stillbirths and deaths; Accuracy of preliminary data not measured by condition; Time from diagnosis to referral not tracked

Access

Prevention reach depends on what people can obtain

Preconception care is an access problem as much as a clinical one. A best evidence summary drew on 17 guidance publications and synthesized 14 evidence statements on folic acid supplementation.^[12] Key recommendations included starting supplementation at least three months before conception, continuing through the first trimester, and recognizing that diet alone is insufficient.^[12] The summary was framed for health systems in regions without mandatory fortification.^[12]

Those recommendations only work if women of reproductive age reach care before pregnancy. Many health systems see these patients in primary care, family planning and chronic disease clinics rather than prenatal visits. Each of those settings is an access point that a preconception pathway can use. A simple prompt in the record, linked to a standard counseling script, can reach patients who are not yet planning pregnancy. The test of access is whether a patient leaves any of those visits knowing the next step, not whether a pamphlet was available.

Food supply is a parallel access route. Eight years after voluntary fortification of corn masa flour was permitted in the United States, researchers surveyed 111 stores in areas with majority Hispanic census tracts.^[13] Half of distinct corn masa flour bags (25 of 50) were fortified, but only 2 of 178 tortilla products (1%) and about 3% of tostadas were.^[13] Very few ready-made products were fortified, so dietary access to folic acid remains uneven for communities that rely on corn masa.^[13]

Vaccine access is the clearest prevention success. From 2012 to 2024, the number of countries using rubella-containing vaccine rose from 132 of 194 (68%) to 179 (92%).^[5] Global coverage with the first routine dose rose from 39% to 73%.^[5] A single dose provides lifelong protection, which makes missed vaccination before pregnancy a pathway failure rather than a clinical mystery.^[5]

Diagnostic access also shapes what surveillance can see. For Shuni virus, an emerging infection associated with neurological illness and birth defects in Africa, limited data reflect low clinical awareness and few diagnostic assays.^[6] Researchers established new assays for hospital-based surveillance and found evidence that the virus is a missed cause of acute neurological infection.^[6] In their healthy control group, 9 of 112 people (8%) had antibodies.^[6] Laboratory capacity is therefore part of birth defects prevention, not separate from it. Health systems that serve travelers and immigrant communities should know which infections their laboratories can and cannot detect. That inventory belongs in maternal-child planning, alongside imaging and genetics capacity.

System route

Build continuity before birth, at birth, and beyond.

A reliable route separates population prevention from individualized counseling and keeps families connected after diagnosis.

The route at a glance

Prevent and counsel
Detect and confirm
Refer and treat
Support the journey

Prevent and counsel
Support evidence-based preconception and prenatal care, vaccination, infection prevention, folic acid guidance, and medication review.
Detect and confirm
Coordinate prenatal screening, newborn examination, screening programs, imaging, laboratory testing, and diagnostic disclosure.
Refer and treat
Use condition-specific urgency and closed-loop connections to pediatric, surgical, genetic, rehabilitation, and community services.
Support the journey
Provide plain-language information, care coordination, developmental services, mental health support, and family-led planning.

Reliability rule: Avoid language that implies every birth defect is preventable or that a family caused a condition.

Figure 2

The system route as one flow

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (4 rows)

Figure 2 data: The system route as one flow
Stage	What the stage requires
Prevent and counsel	Support evidence-based preconception and prenatal care, vaccination, infection prevention, folic acid guidance, and medication review.
Detect and confirm	Coordinate prenatal screening, newborn examination, screening programs, imaging, laboratory testing, and diagnostic disclosure.
Refer and treat	Use condition-specific urgency and closed-loop connections to pediatric, surgical, genetic, rehabilitation, and community services.
Support the journey	Provide plain-language information, care coordination, developmental services, mental health support, and family-led planning.

Equity and trust

Gaps follow geography, income and food supply

Equity in congenital care begins with who is counted. In eastern Ethiopia, rural areas had higher neural tube defect birth prevalence than the overall study area, at 128.7 per 10,000 births.^[14] Because many affected pregnancies ended in stillbirth, population prevalence understated the burden seen at birth, particularly in rural areas.^[14] U.S. systems serving rural counties should ask the same question of their own data. Distance to delivery hospitals and specialty centers can also delay confirmation and referral for rural families.

In Bangladesh, limited screening and low awareness contribute to delayed diagnosis and inadequate care.^[3] Similar barriers appear wherever prenatal visits start late or newborn examinations happen outside hospitals. Health systems can track where diagnoses arrive late by geography, payer and language. They can then direct navigation and interpreter support to the communities where the pathway is slowest. Trust grows when families see that the system notices and responds to those gaps.

Food policy carries equity effects. The corn masa study selected areas with majority Hispanic census tracts in California, Georgia and Texas, including a largely rural county.^[13] Few ready-made masa products in those areas were fortified, which means voluntary policy has not reached most ready-made masa products.^[13] Community nutrition programs and prenatal teams can respond locally while policy debates continue. Prenatal education that names fortified options available in local stores is more useful than general advice about diet.

Fortification itself raises equity and ethics questions. One critical review argued that food fortification is widely debated, raises numerous ethical issues, and has broad implications for human health.^[10] A systematic review found that current evidence does not establish independent harm from unmetabolized folic acid.^[15] Leaders should present both points honestly when community partners ask about fortification.

The global picture shows how investment changes outcomes. India’s current fortification policies provide insufficient folic acid for neural tube defect prevention, according to an economic analysis.^[8] That model estimated that mandatory fortification of wheat flour and rice would prevent 4.5 cases and 3.3 deaths per 1,000 births.^[8] It also estimated per capita costs falling from $26.89 to $3.41, a cost-benefit ratio of about 1:78.^[8] Prevention that is cheap at scale still depends on who receives it. The model’s results held across sensitivity analyses that included inadequate fortification compliance.^[8]

Two epidemiologists review data charts on a large monitor in a public health office. — Illustrative image. Half of corn masa flour bags, but very few ready-made masa products, were fortified with folic acid in surveyed stores.^[13]

Human infrastructure

Abstractors, counselors and coordinators carry the pathway

Surveillance is skilled labor. Utah’s process relies on initial medical record review by nonclinical staff followed by clinician-led confirmation.^[1] The study showed that the first step was accurate enough for many conditions to support early referral.^[1] That finding lets programs deploy clinician time where diagnostic discordance is highest, such as complex cardiac defects.^[1] It also suggests a staffing model in which trained nonclinical reviewers handle volume and clinicians focus on the hardest cases.

Population programs have the same need. In the Ethiopian surveillance study, a pediatrician confirmed every neural tube defect diagnosis and classification.^[14] Confirmation by a qualified clinician is a staffing commitment that registries must plan for. Health systems that report to state programs should know who abstracts, who confirms and how long each step takes. Those answers belong in the same workforce plan as nursing and specialty staffing.

Hospital informatics teams are part of the workforce. Electronic case reporting gave Texas timelier and potentially more complete case identification.^[2] Because some electronic signals were not confirmed, human review remains necessary.^[2] Executives should fund both the interface and the abstractors who validate what it sends. Treating surveillance reporting as an unfunded side task is one of the quiet reasons families wait.

Laboratory and infectious disease teams matter too. New assays for Shuni virus had to be built and validated against neutralization tests before surveillance was possible.^[6] Clinical awareness was named as one reason the infection had been missed.^[6] Training clinicians to consider emerging infections in pregnancy and infancy is a workforce task. Infectious disease, obstetric and neonatal teams should share one escalation route when an unusual pattern appears.

Preconception care depends on clinicians who use current guidance. The evidence summary advised against routine folate testing, which can free clinic time for counseling and planning.^[12] Emerging evidence also suggests choline deficiency may be a risk factor for neural tube defects even where folic acid fortification is in place.^[11] Nutrition and prenatal teams need a process for reviewing new evidence before it changes patient education. Care coordinators and navigators then carry that plan to families after diagnosis. Those roles are often grant-funded or part-time, and leaders should know which positions the pathway would lose if funding lapsed.

Operating dashboard

Measure detection, connection, equity, and continuity.

Stratify by condition, geography, race and ethnicity, language, payer, and referral destination.

Four operating signals

Diagnostic closureSpecialty accessFamily understandingSurveillance quality

Each signal pairs an executive question with one candidate local measure, set out below.

Diagnostic closure

Track suspected conditions through confirmation or documented exclusion.

Measure: Cases with completed diagnostic disposition

Specialty access

Measure time from diagnosis to the first clinically indicated specialty visit.

Measure: Median and 90th-percentile days

Family understanding

Confirm families know the diagnosis, next step, contact, and urgent concerns.

Measure: Documented understanding check

Surveillance quality

Audit completeness and timeliness of reportable case data.

Measure: Complete reports submitted on time

Figure 4

The operating system behind the dashboard

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)

Figure 4 data: The operating system behind the dashboard
Operating signal	Candidate owner
Diagnostic closure	Maternal-child quality
Specialty access	Pediatric specialty operations
Family understanding	Quality and equity leaders
Surveillance quality	Care coordination

Handoff workflow

Transfer the diagnosis, uncertainty, and next responsibility.

Families need one current plan while multiple specialists and agencies become involved.

How responsibility moves

Lane 1Prenatal or newborn team3 steps

Lane 2Hospital to specialty care3 steps

Lane 3Clinical care to family support3 steps

Lane

Prenatal or newborn team

Explain what is known and uncertain.
Complete urgent stabilization and testing.
Name the next accountable clinician.

Lane

Hospital to specialty care

Send complete clinical and imaging records.
Confirm referral acceptance and timing.
Address transport, language, and coverage barriers.

Lane

Clinical care to family support

Offer condition-specific resources.
Connect developmental and community services.
Check caregiver needs without assumptions.

Use the name and language preferred by the person and family, and include people with lived experience in pathway design.

Executive scorecard

Ask whether every journey has an accountable next step.

Keep prevention, surveillance, clinical care, and family experience distinct but connected.

Who reviews what

Maternal-child quality
Pediatric specialty operations
Quality and equity leaders
Care coordination

Candidate owners named in the scorecard, confirmed locally.

Use stable definitions and stratify results by site, population, and service line when appropriate.
Signal	Executive question	Accountable owner	Review cadence
Detection	Are suspected cases reaching diagnostic disposition?	Maternal-child quality	Monthly
Access	Which referrals remain unaccepted or unscheduled?	Pediatric specialty operations	Weekly
Equity	Where do completion and delay differ across populations?	Quality and equity leaders	Quarterly
Support	Do families receive a current plan and named contact?	Care coordination	Monthly

Figure 5

Control points for a reliable congenital-condition referral pathway

Figure 5: Control points for a reliable congenital-condition referral pathway
Control point	Risk if missing	Owner	Evidence of control
Electronic case reporting from birth hospitals with chart confirmation	Cases reach the registry late or unconfirmed	Chief medical information officer with state surveillance liaison	Time from birth to registry notification and confirmation rate
Condition-specific rule for referral on preliminary data	Families wait for final confirmation even for stable diagnoses	Maternal-child quality director	Share of stable-condition cases referred before final confirmation
Routine newborn examination with referral tracking	Defects detected late or never referred	Neonatal medical director	Share of identified cases with a completed referral
Preconception and prenatal chronic disease review	Maternal hypertension and diabetes left unmanaged before pregnancy	Women’s health service line lead	Share of women with these conditions seen for preconception planning
Rubella immunity and vaccination check before pregnancy	Preventable congenital rubella risk persists	Primary care and women’s health leaders	Documented immunity or vaccination among patients planning pregnancy
Condition-level surveillance quality review	Low-accuracy diagnoses drive wrong referrals	Surveillance program manager	Positive predictive value by condition, reviewed annually

Control points derived from the cited evidence [1], [2], [3], [5], [12] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Honest messages about prevention and data

Public messages for this observance should be accurate about prevention. A landmark 1991 trial showed a 72% reduction in neural tube defect recurrence with folic acid among women with a prior affected pregnancy.^[10] About 90 countries now fortify cereal grains with folic acid.^[10] The same review concluded that evidence for supplementation in recurrence is strong, while evidence for mandatory fortification is more limited.^[10]

Other reviews read the fortification evidence more favorably. A meta-analysis of 14 observational studies with more than 33 million participants found a 44% lower risk associated with mandatory fortification.^[9] North American studies showed a 54% lower risk.^[9] Communicators can say that fortification and supplementation are both recognized prevention strategies, while noting that study designs differ.^[9]^[10] Messages aimed at clinicians can carry more detail than public messages, but both should rest on the same sources.

Messages should never imply that every birth defect is preventable or that families are to blame. Research on choline and unmetabolized folic acid shows that nutrition science is still developing.^[11]^[15] The unmetabolized folic acid review found observational associations inconsistent and confounded.^[15] Saying what is known, and what is still being studied, builds trust. Plain-language materials should be reviewed with families who have lived experience of a congenital condition before release.

Surveillance data deserve their own communication plan. The rubella report concluded that sustaining elimination requires continued commitment to strengthen immunization and surveillance systems.^[5] Since 2012, 117 of 194 countries (60%) have verified elimination of endemic rubella transmission.^[5] Stories like this help boards see why registry and reporting investments matter. It also found that large outbreaks have become concentrated in fewer countries.^[5]

Measurement is the governance message. Utah’s validation used positive predictive values by condition, a clear and repeatable quality measure.^[1] Health systems can report time from birth to registry notification, time from diagnosis to family referral and completion of the first specialty visit. Those measures show whether every journey really has an accountable next step. Each should be stratified by condition, geography and payer, and reviewed by a named maternal-child quality committee. Publishing a short annual summary for families and community partners turns surveillance into a shared commitment rather than a hidden reporting duty.

A cardiologist chats with a man in his thirties who was born with a heart defect, at an adult clinic. — Illustrative image. Faster surveillance can shorten the time between diagnosis and early intervention referral for families.^[1]

90-day plan

Close one birth-defect pathway gap in 90 days.

Select a condition with known delay, lost referrals, or family-reported fragmentation.

Ninety days, three moves

Days 1–30Trace the journey
Days 31–60Test one connected route
Days 61–90Sustain family-centered care

Days 1–30

Trace the journey

Map detection through first specialty care.
Review 25 recent cases.
Interview families and frontline teams.

Days 31–60

Test one connected route

Standardize referral content and urgency.
Assign a navigator or accountable contact.
Use a plain-language next-step summary.

Days 61–90

Sustain family-centered care

Compare access and closure with baseline.
Embed escalation in standard work.
Set the next goal with family partners.

Figure 6

The 90-day plan on one timeline

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (9 rows)

Figure 6 data: The 90-day plan on one timeline
Window	Action
Days 1–30	Map detection through first specialty care.
Days 1–30	Review 25 recent cases.
Days 1–30	Interview families and frontline teams.
Days 31–60	Standardize referral content and urgency.
Days 31–60	Assign a navigator or accountable contact.
Days 31–60	Use a plain-language next-step summary.
Days 61–90	Compare access and closure with baseline.
Days 61–90	Embed escalation in standard work.
Days 61–90	Set the next goal with family partners.

Every journey matters when every next step is visible.

World Birth Defects Day should move systems beyond awareness toward prevention, respectful diagnosis, coordinated care, and durable family support.

Executive action
Sponsor one closed-loop maternal-child referral redesign and review its diagnostic, specialty-access, and family-understanding measures within 90 days.

Operational readiness verification

Make the observance visible in everyday operations.

World Birth Defects Day becomes meaningful when families receive clear information, respectful choices, coordinated referrals, and one plan across prenatal, neonatal, pediatric, and community care. The weak version is a message without an operating change. The stronger version defines what teams should see, who owns each transition, how exceptions escalate, and how leaders know that the pathway actually closed.

The principal failure mode is that prevention information, prenatal diagnosis, newborn care, specialty coordination, family support, and long-term services can be disconnected. Leaders should test the route with recent cases, frontline staff, patients or community partners, and the teams that receive the next handoff. That review should distinguish a written policy from reliable execution under real workload, staffing, access, and communication conditions.